Giornata mondiale dell'Alzheimer: un romanzo racconta il buio della memoria
La Repubblica,
ROMA. La notizia è di pochi giorni fa: secondo uno studio pubblicato su Nature sarebbe possibile, grazie a un farmaco, l'Aducanum…
ROMA. La notizia è di pochi giorni fa: secondo uno studio pubblicato su Nature sarebbe possibile, grazie a un farmaco, l'Aducanum…
Una de cada tres personas sufrirá demencia a lo largo de su vida. La pérdida progresiva de memoria es una de las consecuencias má…
투여 시와 투여 후 54주째에 촬영된 아밀로이드 PET 이미지 샘플을 통해서 아두카누맙(Aducanumab)이 아밀로이드 플라크를 감소시킨다는 사실이 확인되었다.
Der Kampf gegen die Alzheimer-Krankheit hat bis jetzt nur bittere Früchte hervorgebracht.
About 25 million people around the world have Alzheimer’s disease. Unless a cure is found, that number is expected to triple in…
Das neue Alzheimer-Medikament Aducanumab schürt wieder einmal Hoffnung. Erste Experten sprechen von einem Durchbruch.
Weniger Ablagerungen im Gehirn und weniger geistiger Abbau: Eine Studie gibt Alzheimer-Patienten Hoffnung.
The investigational Alzheimer's disease (AD) treatment aducanumab (Biogen Inc) decreases amyloid plaques, as measured by…
While most media reported on a "game-changing" Alzheimer's drug, neurologists knew that publication in Nature of the full…
Человеческие антитела против патогенного белка, вызывающего болезнь Альцгеймера, уничтожают опасные белковые отложения в мозге бо…
There is marked cortical atrophy in Alzheimer's Disease, associated with loss of gyri and sulci in the temporal lobe and…
Trotz intensiver Forschung ist bislang kein einziges Medikament gegen Alzheimer auf dem Markt.
En studie nylig publisert i tidsskriftet Nature viser lovende resultater etter testing av en medisin som skal fjerne plakk i…
kirstypargeter 3D medical background with magnifying glass examining brain 3D medical background with magnifying glass…
Preliminary clinical trials with a small group of patients suggest that aducanumab, a drug being developed by Biogen, may be…
An initial trial of an antibody therapy that targets Alzheimer’s disease has shown promising results and could signal a long-awai…
London, Sep 1 (IANS): Researchers have developed a new antibody that has the potential to completely remove the harmful beta-amyl…
Image copyright Thinkstock محققان در آمریکا امیدوارند به ساخت داروی آلزایمر نزدیک شده باشند.
Los pacientes y los familiares de personas con alzhéimer podrían tener una nueva esperanza a corto plazo.
A new drug known as aducanumab has been shown to reduce brain plaque in Alzheimer's patients.
.. Biogen, a biotechnology company, found an antibody working against development of amyloid plaques in brain of those…
Une petite étude montre qu'un anticorps, l’aducanumab, peut limiter la progression des plaques amyloïdes et ralentir le déclin…
È l’anticorpo monoclonale Aducanumab, che in un piccolo studio ha dimostrato di eliminare le placche e ridurre la progressione…
Hannover. Das vom US-Pharmakonzern Biogen entwickelte "Aducanumab" zerstört und entfernt Amyloid-Ablagerungen im Gehirn.
Hannover. Das vom US-Pharmakonzern Biogen entwickelte "Aducanumab" zerstört und entfernt Amyloid-Ablagerungen im Gehirn.
Ciência
Scientists have developed an antibody that can completely clear the harmful plaques linked to Alzheimer's, as well as slow…
"A revolutionary drug that could stop people from ever developing Alzheimer's disease has been unveiled," the Daily Mail reports.
"A revolutionary drug that could stop people from ever developing Alzheimer's disease has been unveiled," the Daily Mail reports.
The Daily Extra, Company News Published on Thursday, September 1, 2016 FDA granted Fast Track designation to Biogen Inc.
In what some experts are hailing as a major breakthrough in the field of Alzheimer’s research, a new investigational drug was…
Un nouvel espoir pour les personnes atteintes de la maladie d’Alzheimer apparaît enfin dans les résultats d’une étude clinique…
Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab Granted FDA Fast Track Designation Company Also Provides…
The Daily Extra, Company News Published on Thursday, September 1, 2016 FDA granted Fast Track designation to Biogen Inc.
In what some experts are hailing as a major breakthrough in the field of Alzheimer’s research, a new investigational drug was…
Company Also Provides Update On New Interim Analysis From Phase 1b Study CAMBRIDGE, Mass.
En medisin som bryter ned avleiringene av stoffet amyloid, som bygger seg opp i hjernen til pasienter med Alzheimer, har så…
] Today Biogen (NASDAQ: BIIB) announced that aducanumab, its investigational treatment for early Alzheimer's disease (AD), was…
Company Also Provides Update On New Interim Analysis From Phase 1b Study CAMBRIDGE, Mass.
Sept. 1, 2016 20:01 UTC Company Also Provides Update On New Interim Analysis From Phase 1b Study CAMBRIDGE, Mass.--( BUSINESS…
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Today Biogen ( BIIB ) announced that aducanumab, its investigational treatment for early…
Company Also Provides Update On New Interim Analysis From Phase 1b Study Today Biogen (NASDAQ: BIIB) announced that aducanumab…
Today Biogen (NASDAQ: BIIB) announced that aducanumab, its investigational treatment for early Alzheimer’s disease (AD), was…
A new Alzheimer’s disease drug may be able to clear away goopy piles of toxic proteins in patients' brains—hallmarks of the…
Today Biogen (NASDAQ: BIIB) announced that aducanumab, its investigational treatment for early Alzheimer’s disease (AD), was…
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Today Biogen (NASDAQ: BIIB ) announced that aducanumab, its investigational treatment for…
CAMBRIDGE, Mass.--(Business Wire)--Today Biogen (NASDAQ: BIIB) announced that aducanumab, its investigational treatment for…
CAMBRIDGE, Mass.--( BUSINESS WIRE )--Today Biogen (NASDAQ: BIIB) announced that aducanumab, its investigational treatment for…
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Today Biogen ( BIIB ) announced that aducanumab, its investigational treatment for early…
Today Biogen (NASDAQ: BIIB) announced that aducanumab, its investigational treatment for early Alzheimer’s disease (AD), was…
London: Researchers have developed a new antibody that has the potential to completely remove the harmful beta-amyloid plaques -…
SIGN UP FOR OUR NEWSLETTER WASHINGTON, Sept. 1 (UPI) — An experimental drug showed promise at clearing proteins in the brain…
WASHINGTON, Sept. 1 (UPI) -- An experimental drug showed promise at clearing proteins in the brain linked to the development of…
giovedì 01/09/2016 di Michele Iacovone in Alzheimer Un nuovo farmaco contro l’Alzheimer sarebbe in grado di ridurre le placche…
London, Sep 1 : Researchers have developed a new antibody that has the potential to completely remove the harmful beta-amyloid…
Thursday September 1 2016 The exact cause of Alzheimer's is still unknown "A revolutionary drug that could stop people from…
Trials of a drug used to reduce the amount of amyloid is being hailed as a potentially “game changing” treatment – or even a “pre…
One of the main venues of research in the fight against alzheimer’s disease is “plaque fighting” treatments.
Biogen’s Alzheimer’s disease treatment reduced amyloid plaque in patients’ brains in an early-stage trial, in what is being…
Mahdollinen läpimurto Alzheimerin hoidossa – vasta-aine lievensi potilaiden oireita Kansainvälinen tutkijaryhmä on onnistunut…
In people with Alzheimers disease, a new investigational drug can dramatically reduce the amount of amyloid beta plaque, the…
A klinikai vizsgálatok szerint biztonságos az az új Alzheimer-gyógyszer, amely ez első eredmények alapján sikeresen szünteti…
In people with Alzheimer’s disease, a new investigational drug can dramatically reduce the amount of amyloid beta plaque, the…
A new experimental Alzheimer's drug – aducanumab – cleared out protein build-up in the brains of people suffering from mild…
"A revolutionary drug that could stop people from ever developing Alzheimer's disease has been unveiled," the Daily Mail reports.
Mancano 16 giorni al Wired Next Fest. Scopri il programma È l’anticorpo monoclonale Aducanumab, che in un piccolo studio ha…
1 settembre 2016 - - Stampa È l’anticorpo monoclonale Aducanumab, che in un piccolo studio ha dimostrato di eliminare le…
Quella di Alzheimer è la malattia neurodegenerativa più diffusa al mondo. Non solo non esiste ancora una cura, ma anche le sue…
CTVNews.ca Staff Published Thursday, September 1, 2016 9:48AM EDT The landscape of Alzheimer’s disease treatments is littered…
An experimental Alzheimer’s drug may have brought researchers one step closer to preventing the disease altogether.
Aducanumab, which is an antibody, has been synthesized in the lab in order to be used in the armor of medical weapons against…
La rivista Nature dedica la copertina a un nuovo farmaco che sarebbe in grado di ridurre in modo significativo l’accumulo di…
An initial trial of an antibody therapy that targets Alzheimer’s disease has shown promising results and could signal a long-awai…
Results from pre-clinical research and PRIME, the Phase 1b study of Biogenâs (NASDAQ: BIIB) investigational treatment for…
In people with Alzheimer's disease, a new investigational drug can dramatically reduce the amount of amyloid beta plaque, the…
01.09.2016 Der von der Universität Zürich entwickelte Antikörper Aducanumab führt bei Patienten mit frühen Formen von Alzheimer…
London, Sep 1 (IANS) Researchers have developed a new antibody that has the potential to completely remove the harmful beta-amylo…
London, Sep 1 (IANS) Researchers have developed a new antibody that has the potential to completely remove the harmful beta-amylo…
Home News Health Headlines Amid push to reduce suicides, local hotline needs volunteers Experts say cooler temperatures may…
Welcome to the worst month for stocks of the year, even though the reason it’s such a bummer of a month is a bit of a mystery.
A insubordinate drug that could stop people from ever building Alzheimer’s illness has been denounced by scientists.
Medizin Donnerstag, 1. September 2016 Beta-Amyloid Cambridge Wchentliche Injektionen des monoklonalen Antikrpers Aducanumab…
Memories don't get 'written' into the long-term memory banks of dementia sufferers.
Peter Byrne/PA An antibody has significantly reduced levels of beta amyloid protein in people with Alzheimer’s disease…